THE $44.55 BILLION OPPORTUNITY:
AUTOLOGOUS CELL THERAPY’S NEXT HEALTHCARE MEGA-TREND The Market Size Debate and Why Methodology Matters Financial journalists frequently cite a single market projection as definitive: autologous cell therapy will reach $44.55 billion by 2033. This figure originates from Astute Analytica’s research, which projects growth from $10.12 billion in 2024 at a 17.90% compound annual growth rate. […]
From Trading Floors to Cellular Therapy:
Diederik van der Reijt’s Mission to Democratize Regenerative Medicine A Personal Journey Sparked by Loss and Hope The transformation of Diederik van der Reijt from high-frequency trading executive to biotech visionary began with two profound personal experiences that would forever shape his understanding of healthcare’s inequities. When his close friend and colleague Ben received a […]
INCLUSIVE HEALTHCARE:
CELLJEVITY’S MISSION TO BROADEN ACCESS TO ADVANCED THERAPIES In an era when medical breakthroughs often appear out of reach for many regions, the Dutch-founded biotech firm Celljevity is taking a path it believes may help deliver advanced therapies worldwide. Led by entrepreneur Diederik van der Reijt, the company reports treating over 1,000 patients with its […]
The Science of Telomeres:
How Celljevity’s Approach to Cellular Aging Differs from Traditional Longevity Research The longevity industry has exploded into a $27 trillionglobal market, fueled by promises of extended healthspan and the tantalizing possibility of reversing biological age. Yet beneath the marketing hype lies a fundamental question: Are we merely slowing the march of time, or can we […]